Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.70 |
| ▸ | ITGAV | P06756 | 20/20 | 0.70 |
| ▸ | ITGB5 | P18084 | 8/20 | 0.68 |
| ▸ | ITGB6 | P18564 | 8/20 | 0.68 |
| ▸ | ITGB8 | P26012 | 8/20 | 0.68 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7008303 | 1.00 | ITGB3 (0.70) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL7009188 | 0.89 | ITGB3 (0.57) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL7009184 | 0.89 | ITGB3 (0.57) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL6422734 | 0.89 | ITGB3 (0.85) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL6422730 | 0.89 | ITGB3 (0.85) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL7374380 | 0.88 | ITGB3 (0.74) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL7006493 | 0.85 | ITGAV (0.52) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL7549076 | 0.80 | ITGB3 (0.74) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL6421075 | 0.79 | ITGAV (0.78) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL6421324 | 0.78 | ITGB3 (0.67) | ITGB3ITGAVITGB5ITGB6ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946165-B1 | INTEGRIN ANTAGONISTS | MERCK & CO INC (US) | 2003-04-09 | — | — | EP | claimed |
| JP-2001524079-A | — | — | 2001-11-27 | — | — | JP | claimed |
| EP-0973396-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | claimed |
| EP-0973396-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-01-26 | — | — | EP | claimed |
| WO-1998044797-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1998-10-15 | — | — | WO | claimed |
| EP-0946165-B1 | INTEGRIN ANTAGONISTS | MERCK & CO INC (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-0973396-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-0973396-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998044797-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1998-10-15 | — | — | WO | disclosed |